95 related articles for article (PubMed ID: 14739666)
1. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
Varuni Kondagunta G; Bacik J; Schwartz L; Sheinfeld J; Bajorin D; Vuky J; Marion S; Mazumdar M; Bosl GJ; Motzer RJ
Invest New Drugs; 2004 Apr; 22(2):177-9. PubMed ID: 14739666
[TBL] [Abstract][Full Text] [Related]
2. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.
Vuky J; McCaffrey J; Ginsberg M; Mariani T; Bajorin DF; Bosl GJ; Motzer RJ
Invest New Drugs; 2000 Aug; 18(3):265-7. PubMed ID: 10958596
[TBL] [Abstract][Full Text] [Related]
4. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.
Motzer RJ; Bajorin DF; Schwartz LH; Hutter HS; Bosl GJ; Scher HI; Lyn P; Fischer P
J Clin Oncol; 1994 Nov; 12(11):2277-83. PubMed ID: 7525885
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Schmoll HJ; Natt F; Knoche M; Beyer J; Souchon R
J Cancer Res Clin Oncol; 1994; 120(12):754-7. PubMed ID: 7798304
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors.
Puc HS; Bajorin DF; Bosl GJ; Amsterdam A; Motzer RJ
Invest New Drugs; 1995; 13(2):163-5. PubMed ID: 8617580
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of relapse or refractory germ cell tumor who had been treated with combination chemotherapy of cisplatin and carboplatin].
Kiyama Y; Suzuki G; Masauzi N; Ohizumi H; Kobayashi N; Ogasawara M; Naohara T; Saito M; Higa T; Kasai M
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1989-92. PubMed ID: 8978809
[TBL] [Abstract][Full Text] [Related]
10. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors.
Koul S; McKiernan JM; Narayan G; Houldsworth J; Bacik J; Dobrzynski DL; Assaad AM; Mansukhani M; Reuter VE; Bosl GJ; Chaganti RS; Murty VV
Mol Cancer; 2004 May; 3():16. PubMed ID: 15149548
[TBL] [Abstract][Full Text] [Related]
11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of long-term results of a modified VAB-6 chemotherapy regimen in a cohort of good-risk metastatic non seminomatous germ-cell tumors.
Culine S; Philippot I; Farhat F; Théodore C; Terrier-Lacombe MJ; Droz JP
Bull Cancer; 1997 Apr; 84(4):368-72. PubMed ID: 9238159
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
Beyer J; Kingreen D; Krause M; Schleicher J; Schwaner I; Schwella N; Huhn D; Siegert W
Cancer; 1997 Jan; 79(1):161-8. PubMed ID: 8988741
[TBL] [Abstract][Full Text] [Related]
14. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
[TBL] [Abstract][Full Text] [Related]
15. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
Loehrer PJ; Einhorn LH; Williams SD
J Clin Oncol; 1986 Apr; 4(4):528-36. PubMed ID: 3633952
[TBL] [Abstract][Full Text] [Related]
16. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Johnson D; Elson P; Einhorn LH; Trump D
J Clin Oncol; 1995 Feb; 13(2):470-6. PubMed ID: 7531223
[TBL] [Abstract][Full Text] [Related]
17. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
[TBL] [Abstract][Full Text] [Related]
18. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M
Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
